CA2261813A1 - Pharmaceutical composition containing a 5ht2c antagonist and a d2 antagonist - Google Patents
Pharmaceutical composition containing a 5ht2c antagonist and a d2 antagonist Download PDFInfo
- Publication number
- CA2261813A1 CA2261813A1 CA002261813A CA2261813A CA2261813A1 CA 2261813 A1 CA2261813 A1 CA 2261813A1 CA 002261813 A CA002261813 A CA 002261813A CA 2261813 A CA2261813 A CA 2261813A CA 2261813 A1 CA2261813 A1 CA 2261813A1
- Authority
- CA
- Canada
- Prior art keywords
- antagonist
- compound
- pharmaceutically acceptable
- 5ht2c
- antagonist activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9615767.2A GB9615767D0 (en) | 1996-07-26 | 1996-07-26 | Novel treatment |
| GB9615767.2 | 1996-07-26 | ||
| PCT/EP1997/004159 WO1998004289A2 (en) | 1996-07-26 | 1997-07-22 | Pharmaceutical composition containing a 5ht2c antagonist and a d2 antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2261813A1 true CA2261813A1 (en) | 1998-02-05 |
Family
ID=10797573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002261813A Abandoned CA2261813A1 (en) | 1996-07-26 | 1997-07-22 | Pharmaceutical composition containing a 5ht2c antagonist and a d2 antagonist |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0936924A2 (hu) |
| JP (1) | JP2000516924A (hu) |
| KR (1) | KR20000029564A (hu) |
| CN (1) | CN1230894A (hu) |
| AR (1) | AR008083A1 (hu) |
| AU (1) | AU725817B2 (hu) |
| BR (1) | BR9710568A (hu) |
| CA (1) | CA2261813A1 (hu) |
| CO (1) | CO5031292A1 (hu) |
| CZ (1) | CZ23799A3 (hu) |
| GB (1) | GB9615767D0 (hu) |
| HU (1) | HUP9903619A3 (hu) |
| IL (1) | IL128219A0 (hu) |
| NO (1) | NO990322L (hu) |
| NZ (1) | NZ333813A (hu) |
| PL (1) | PL331426A1 (hu) |
| TR (1) | TR199900140T2 (hu) |
| WO (1) | WO1998004289A2 (hu) |
| ZA (1) | ZA976593B (hu) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9612883D0 (en) * | 1996-06-20 | 1996-08-21 | Smithkline Beecham Plc | Novel compounds |
| US6174882B1 (en) | 1998-11-23 | 2001-01-16 | Sepracor Inc. | 2-hydroxymethylolanzapine compositions and methods |
| CA2351718A1 (en) | 1998-11-23 | 2000-06-02 | Sepracor Inc. | Desmethylolanzapine compositions and methods |
| WO2000030649A1 (en) * | 1998-11-23 | 2000-06-02 | Sepracor Inc. | Pharmaceutical compositions containing olanzapine-n-oxide |
| WO2000054764A2 (en) * | 1999-03-18 | 2000-09-21 | Children's Hospital Research Foundation | A method of treating bulimia nervosa and related eating disorders by administration of atypical antipsychotic medications |
| EP1223939A1 (en) * | 1999-05-19 | 2002-07-24 | AstraZeneca AB | Method of treating weight gain |
| WO2005013969A1 (en) * | 2003-07-15 | 2005-02-17 | Janssen Pharmaceutica N.V. | Antipsychotic agent with socializing properties |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9500998D0 (sv) * | 1995-03-19 | 1995-03-19 | Haakan Wilhelm Wikstroem | New sulfone ester analogues of iso-clozapine and related structures: atypical neuroleptics |
-
1996
- 1996-07-26 GB GBGB9615767.2A patent/GB9615767D0/en active Pending
-
1997
- 1997-07-22 HU HU9903619A patent/HUP9903619A3/hu unknown
- 1997-07-22 BR BR9710568A patent/BR9710568A/pt not_active Application Discontinuation
- 1997-07-22 KR KR1019997000622A patent/KR20000029564A/ko not_active Application Discontinuation
- 1997-07-22 CZ CZ99237A patent/CZ23799A3/cs unknown
- 1997-07-22 PL PL97331426A patent/PL331426A1/xx unknown
- 1997-07-22 CN CN97197977A patent/CN1230894A/zh active Pending
- 1997-07-22 WO PCT/EP1997/004159 patent/WO1998004289A2/en not_active Application Discontinuation
- 1997-07-22 JP JP10508522A patent/JP2000516924A/ja active Pending
- 1997-07-22 AU AU42972/97A patent/AU725817B2/en not_active Ceased
- 1997-07-22 IL IL12821997A patent/IL128219A0/xx unknown
- 1997-07-22 EP EP97918947A patent/EP0936924A2/en not_active Ceased
- 1997-07-22 CA CA002261813A patent/CA2261813A1/en not_active Abandoned
- 1997-07-22 NZ NZ333813A patent/NZ333813A/xx unknown
- 1997-07-22 TR TR1999/00140T patent/TR199900140T2/xx unknown
- 1997-07-24 ZA ZA976593A patent/ZA976593B/xx unknown
- 1997-07-24 AR ARP970103348A patent/AR008083A1/es not_active Application Discontinuation
- 1997-07-25 CO CO97042582A patent/CO5031292A1/es unknown
-
1999
- 1999-01-25 NO NO990322A patent/NO990322L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA976593B (en) | 1999-01-25 |
| HUP9903619A2 (hu) | 2000-10-28 |
| HUP9903619A3 (en) | 2001-03-28 |
| NO990322L (no) | 1999-03-24 |
| PL331426A1 (en) | 1999-07-19 |
| WO1998004289A3 (en) | 1998-03-19 |
| KR20000029564A (ko) | 2000-05-25 |
| EP0936924A2 (en) | 1999-08-25 |
| CN1230894A (zh) | 1999-10-06 |
| WO1998004289A2 (en) | 1998-02-05 |
| CZ23799A3 (cs) | 1999-06-16 |
| IL128219A0 (en) | 1999-11-30 |
| NO990322D0 (no) | 1999-01-25 |
| BR9710568A (pt) | 1999-08-17 |
| NZ333813A (en) | 2000-07-28 |
| GB9615767D0 (en) | 1996-09-04 |
| AU4297297A (en) | 1998-02-20 |
| CO5031292A1 (es) | 2001-04-27 |
| TR199900140T2 (xx) | 1999-03-22 |
| JP2000516924A (ja) | 2000-12-19 |
| AU725817B2 (en) | 2000-10-19 |
| AR008083A1 (es) | 1999-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6642228B1 (en) | α1b-adrenergic receptor antagonists | |
| US20040186102A1 (en) | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | |
| US20090023773A1 (en) | Compositions and methods for modulating gated ion channels | |
| US20070197509A1 (en) | Compositions and methods for modulating gated ion channels | |
| SK10832002A3 (sk) | Deriváty 1,3-dihydro-2H-indol-2-ónu, spôsob ich prípravy a farmaceutická kompozícia, ktorá ich obsahuje | |
| JP2001518895A (ja) | ソマトスタチン作働薬 | |
| JP2002535331A (ja) | 新規血管形成阻害薬 | |
| JPH07291964A (ja) | 新規ベンズイミダゾ−ルのピペリジン誘導体 | |
| JPH08253474A (ja) | インドールピペリジン誘導体 | |
| JPH09502177A (ja) | ５ｈｔ１ｄレセプター拮抗薬用インドールおよびインドリン誘導体 | |
| JPH09501171A (ja) | ５ｈｔ１ｄ受容体アンタゴニストとしてのアミド誘導体 | |
| JP2005525332A (ja) | ５−ｈｔ６受容体アフィニティーを有するスルホニル化合物 | |
| WO1997008167A1 (en) | 5ht2c and 5ht2b antagonists | |
| IE51551B1 (en) | Isoquinoline derivatives,process for their preparation and pharmaceutical formulations containing them and their use | |
| CN111548345A (zh) | 一类苯并咪唑类衍生物及其制备方法和应用 | |
| EP0912556B1 (en) | Indoline derivatives useful as 5-ht-2c receptor antagonists | |
| CA2261813A1 (en) | Pharmaceutical composition containing a 5ht2c antagonist and a d2 antagonist | |
| NO142838B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive isokinolinderivater. | |
| US5175158A (en) | Condensed diazepinones, processes for preparing them and pharmaceutical compositions containing these compounds | |
| JP5062938B2 (ja) | セロトニン受容体及びドーパミン受容体にアフィニティーを有する新規ｎ，ｎ’−二置換ベンゾイミダゾロン誘導体 | |
| TW382015B (en) | Pyridin-3-yloxy-pyridin- or pyridazin-3-ylcarbamoyl-indoline derivatives having 5HT2c receptor antagonist activity, a process for the preparation thereof, and a pharmaceutical composition comprising them | |
| JPH03218356A (ja) | トランス―４―アミノ（アルキル）―１―ピリジルカルバモイルシクロヘキサン化合物およびその医薬用途 | |
| NO143744B (no) | Analogifremgangsmaate for fremstilling av fysiologisk aktive benz(de)isokinolin-derivater | |
| CN102770431A (zh) | [4[4-(5-氨基甲基-2-氟-苯基)-哌啶-1-基]-(1h-吡咯并吡啶-基)-甲酮及其合成 | |
| US6159941A (en) | Use of somatostatin agonists and antagonists for treating diseases related to the eye |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |